Effects of taurine on blood sugar and inflammation in people with Type 2 diabetes
Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial
This study is testing if taking taurine can help people with Type 2 diabetes better control their blood sugar and reduce inflammation.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 30 Years to 80 Years |
| Sex | All |
| Sponsor | Hospital de Clinicas de Porto Alegre Academic / other |
| Locations | 1 site (Porto Alegre, Rio Grande do Sul) |
| Trial ID | NCT04874012 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of taurine, a semi-essential amino acid, on glycemic control, lipid levels, and inflammation in individuals diagnosed with Type 2 diabetes mellitus (DM2). A total of 94 participants will be randomly assigned to receive either taurine or a placebo for 12 weeks, with various blood and urine tests conducted to assess changes in key health markers. The study aims to determine if taurine can improve health outcomes for those who struggle to meet glycemic targets with conventional treatments. Participants will also be monitored for adverse effects throughout the trial.
Who should consider this trial
Good fit: Ideal candidates include adults over 30 years old with a clinical diagnosis of Type 2 diabetes for at least 6 months and specific HbA1c levels.
Not a fit: Patients with chronic renal failure, recent myocardial infarction, or those currently using certain medications or supplements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new adjunctive treatment option for individuals with Type 2 diabetes who have difficulty achieving glycemic control.
How similar studies have performed: While pre-clinical studies suggest taurine may be beneficial, there are currently no well-conducted clinical studies evaluating its effects on glycated hemoglobin in humans, making this approach novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Female and male individuals, with clinical diagnosis of DM2 for at least 6 months; * Age over 30 years; * BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months; * HbA1c between 7.5% and 10.5%. Exclusion criteria * Use of herbal supplements, antioxidants, and multivitamins in the last 3 months; * Pregnancy or lactation; * Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h; * Myocardial infarction in the last than 6 months * Current neoplasia; * Chronic use of glucocorticoids; * Bariatric surgery.
Where this trial is running
Porto Alegre, Rio Grande do Sul
- Hospital de Clínicas — Porto Alegre, Rio Grande do Sul, Brazil (Recruiting)
Study contacts
- Principal investigator: Beatriz D Schaan, PhD — Hospital de Clínicas de Porto Alegre
- Study coordinator: Beatriz D Schaan, PhD
- Email: bschaan@hcpa.edu.br
- Phone: 55 51 3359-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.